Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
-SEC Filing
Stocks · News reference
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.
Morgan Stanley Initiates Coverage On Achieve Life Sciences with Overweight Rating, Announces Price Target of $13
Morgan Stanley analyst Maxwell Skor initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Overweight rating and announces Price Target of $13.
Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.16) by 400 percent. This is a 116.22 percent decrease over losses of $(0.37) per